Autologous dermal fibroblast injections slow atrioventricular conduction and ventricular rate in atrial fibrillation in swine

Circulation: Arrhythmia and Electrophysiology

Volumn 8, Issue 2, 2015, Pages 439-446

  Tondato, Fernando ^a,b   Zeng, Hong ^b   Goodchild, Traci ^b   Ng, Fu Siong ^b   Chronos, Nicolas ^b   Peters, Nicholas S ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b Saint Joseph's Hospital of Atlanta   (United States)

Author keywords

Atrioventricular node; cell transplantation; fibroblasts

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATRIAL FIBRILLATION; ATRIOVENTRICULAR CONDUCTION; AUTOLOGOUS DERMAL FIBROBLAST TRANSPLANTATION; CARDIAC MAPPING SYSTEM; CELL TRANSPLANTATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; ENDOCARDIAL INJECTION CATHETER; FIBROBLAST; FIBROBLAST CULTURE; FOLLOW UP; GEOMETRY; HEART ELECTROPHYSIOLOGY; HEART RATE; HEART RIGHT ATRIUM; HISTOLOGY; IMPLANTATION; INJECTION; NONHUMAN; PIG; PRIORITY JOURNAL; SINUS RHYTHM; TELEMETRY; THREE DIMENSIONAL IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; ACTION POTENTIAL; ANIMAL; AUTOTRANSPLANTATION; CELL CULTURE; CYTOLOGY; DERMIS; DISEASE MODEL; ELECTROCARDIOGRAPHY; HEART ATRIOVENTRICULAR NODE; HEART FUNCTION TEST; HEART PACING; HEART VENTRICLE; HEART VENTRICLE FUNCTION; PATHOLOGY; PATHOPHYSIOLOGY; TIME; TRANSPLANTATION;

ACTION POTENTIALS; ANIMALS; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE; CARDIAC PACING, ARTIFICIAL; CELLS, CULTURED; DERMIS; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY, AMBULATORY; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FIBROBLASTS; HEART VENTRICLES; INJECTIONS; SUS SCROFA; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; VENTRICULAR FUNCTION;

EID: 84932156601     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.114.001536     Document Type: Article

References (29)

1. Janko S, Dorwarth U, Hoffmann E. Pharmacotherapy of atrial fibrillation: an old option with new possibilities. Expert Opin Pharmacother. 2008;9:913-925. doi: 10.1517/14656566.9.6.913.
2. Lip GY, Tse HF. Management of atrial fibrillation. Lancet. 2007;370:604-618. doi: 10.1016/S0140-6736(07)61300-2.
3. Cleland JG, Coletta AP, Buga L, Ahmed D, Clark AL. Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR. Eur J Heart Fail. 2010;12:623-629. doi: 10.1093/eurjhf/hfq083.
4. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ, Jr., Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (hrs) task force on catheter and surgical ablation of atrial fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9:632-696 e621.
5. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-2677. doi: 10.1056/NEJMoa0708789.
6. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840. doi: 10.1056/NEJMoa021375.
7. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833. doi: 10.1056/NEJMoa021328.
8. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, Weerasooriya R. Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. Europace. 2007;9:498-505. doi: 10.1093/europace/eum091.
9. Feld GK. Atrioventricular node modification and ablation for ventricular rate control in atrial fibrillation. Heart Rhythm. 2007;4(3 Suppl):S80-S83. doi: 10.1016/j.hrthm.2006.12.007.
10. Zhang Y, Mazgalev TN. Ventricular rate control during atrial fibrillation and AV node modifications: past, present, and future. Pacing Clin Electrophysiol. 2004;27:382-393.
11. Fine GC, Liao R, Sohn RL. Cell therapy for cardiac repair. Panminerva Med. 2008;50:129-137.
12. Srivastava D, Ivey KN. Potential of stem-cell-based therapies for heart disease. Nature. 2006;441:1097-1099. doi: 10.1038/nature04961.
13. Wollert KC. Cell therapy for acute myocardial infarction. Curr Opin Pharmacol. 2008;8:202-210. doi: 10.1016/j.coph.2007.12.011.
14. Yamahara K, Nagaya N. Stem cell implantation for myocardial disorders. Curr Drug Deliv. 2008;5:224-229.
15. Clavel C, Verfaillie CM. Bone-marrow-derived cells and heart repair. Curr Opin Organ Transplant. 2008;13:36-43. doi: 10.1097/MOT.0b013e3282f428d1.
16. Evans SM, Mummery C, Doevendans PA. Progenitor cells for cardiac repair. Semin Cell Dev Biol. 2007;18:153-160. doi: 10.1016/j. semcdb.2006.12.009.
17. Roccio M, Goumans MJ, Sluijter JP, Doevendans PA. Stem cell sources for cardiac regeneration. Panminerva Med. 2008;50:19-30.
18. Siminiak T, Kalmucki P, Kurpisz M. Autologous skeletal myoblasts for myocardial regeneration. J Interv Cardiol. 2004;17:357-365. doi: 10.1111/j.1540-8183.2004.04077.x.
19. Beeres SL, Atsma DE, van der Laarse A, Pijnappels DA, van Tuyn J, Fibbe WE, de Vries AA, Ypey DL, van der Wall EE, Schalij MJ. Human adult bone marrow mesenchymal stem cells repair experimental conduction block in rat cardiomyocyte cultures. J Am Coll Cardiol. 2005;46:1943-1952. doi: 10.1016/j.jacc.2005.07.055.
20. van Veen TA, de Bakker JM, van der Heyden MA. Mesenchymal stem cells repair conduction block. J Am Coll Cardiol. 2006;48:219-20, author reply 220. doi: 10.1016/j.jacc.2006.04.006.
21. Bunch TJ, Mahapatra S, Bruce GK, Johnson SB, Miller DV, Horne BD, Wang XL, Lee HC, Caplice NM, Packer DL. Impact of transforming growth factor-beta1 on atrioventricular node conduction modification by injected autologous fibroblasts in the canine heart. Circulation. 2006;113:2485-2494. doi: 10.1161/CIRCULATIONAHA.105.570796.
22. Kwaku KF. Cell therapy for rate control in atrial fibrillation: a new approach to an old problem. Circulation. 2006;113:2474-2476. doi: 10.1161/CIRCULATIONAHA.106.626689.
23. Cavallini M. Autologous fibroblasts to treat deep and complicated leg ulcers in diabetic patients. Wound Repair Regen. 2007;15:35-38. doi: 10.1111/j.1524-475X.2006.00182.x.
24. Karchilaki I, Topakas G, Castana O, Sotiriou P, Michelakis D, Alexakis D, Giokas CS. The use of cultured autologous fibroblasts in burn wounds healing process. Burns. 2007;33:791-792. doi: 10.1016/j. burns.2006.08.023.
25. Keller G, Sebastian J, Lacombe U, Toft K, Lask G, Revazova E. Safety of injectable autologous human fibroblasts. Bull Exp Biol Med. 2000;130:786-789.
26. Lamme EN, Van Leeuwen RT, Brandsma K, Van Marle J, Middelkoop E. Higher numbers of autologous fibroblasts in an artificial dermal substitute improve tissue regeneration and modulate scar tissue formation. J Pathol. 2000;190:595-603. doi: 10.1002/(SICI)1096-9896(200004)190:53.0.CO;2-V.
27. Wong T, McGrath JA, Navsaria H. The role of fibroblasts in tissue engineering and regeneration. Br J Dermatol. 2007;156:1149-1155. doi: 10.1111/j.1365-2133.2007.07914.x.
28. Gaudesius G, Miragoli M, Thomas SP, Rohr S. Coupling of cardiac electrical activity over extended distances by fibroblasts of cardiac origin. Circ Res. 2003;93:421-428. doi: 10.1161/01.RES.0000089258.40661.0C.
29. Kizana E, Ginn SL, Allen DG, Ross DL, Alexander IE. Fibroblasts can be genetically modified to produce excitable cells capable of electrical coupling. Circulation. 2005;111:394-398. doi: 10.1161/01. CIR.0000153812.64956.EF.